Why the study?
To analyze the research trajectory, development characteristics, hotspots, and emerging frontiers of ginseng in cardiovascular disease prevention and treatment from 1998 to 2025 to promote clinical translation.
This bibliometric analysis reveals rapid growth in ginseng cardiovascular research since 2019, primarily driven by Asian countries and focused on preclinical pharmacological mechanisms, highlighting a major gap in clinical translation.
Bibliometric mapping of ginseng in CVD highlights gaps; leaves open any clinical role pending randomized trials.
Meyer (ginseng), as a herbal remedy with a long historical usage, is extensively utilized in the field of complementary and alternative medicine. This review was based on the Web of Science core collection, searching and screening for relevant studies on "ginseng" and "cardiovascular disease". Subsequently, the target literature records were analyzed and visualized using CiteSpace, Scimago Graphica, Bibliometrix R software package, and Microsoft Excel. This review summarized the research trajectory of ginseng in the prevention and treatment of CVDs from 1998 to 2025, analyzed its development characteristics, research hotspots and emerging frontiers, in order to provide new methods for the application of herbal medicine and promote clinical translation and the integration of complementary and alternative medicine with modern medical practice, demonstrating the enormous potential of ginseng in the prevention and treatment of CVDs.
No takes yet. Share an insight, caveat, or question.
Lan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: